We tested the novel filter device Claristep® for the preparation of protein samples containing one of four different target molecules, i.e. an anti-malaria vaccine candidate, aviscuminum, interferon alfa-2B or monoclonal antibody (mAb) P2G12. In comparison to the standard protocols for sample preparation prior to analysis by either reversed-phase or SEC HPLC, the Claristep® filter did not exhibit a significant difference in protein concentration if the target molecules were present with at least 1.0 g L-1. A significantly reduced product concentration was observed in the Claristep® filtered samples compared to the standard protocol for mAb P2G12 if the concentrations were lower. The protein adsorption to the filter material was well described by a Langmuir adsorption isotherm.Additionally, the Claristep® filters facilitated a rapid sample preparation with minimal volume losses.
Related Articles Read More >

R&D 100 of the day: Park FX40 Atomic Force Microscope
R&D 100 winner of the day: Safety & Reliability with Silicone Solutions for Electric Vehicle Thermal Management

R&D 100 winner of the day: Hydra I/O: A system for highly resilient inter-chip communications
